Discussing the Appropriateness of 2D, 3D, & in vivo Models to Build a Robust Preclinical Data Package in Rare Disease Programs

• Exploring the use of animal models within a program’s means to ensure preclinical work that is predictive into the clinic
• Comparing the advantages and disadvantages of 2D and 3D models for long term rare disease studies in terms of dosing and translatability
• Establishing the importance of a robust preclinical data package and how to achieve this in early strategic development

Speakers:

Sweta Girgenrath

Vice President, Head of Cardiovascular and Neuromuscular and Cardiovascular Therapeutics

Entrada Therapeutics Inc.